Free Trial
→ Did You See Trump’s Manhattan Project Bombshell? (From Banyan Hill Publishing) (Ad)

GlucoTrack Q4 2022 Earnings Report

GlucoTrack logo
$0.12 +0.04 (+47.23%)
As of 01/21/2025 04:00 PM Eastern
Earnings History

GlucoTrack EPS Results

Actual EPS
-$0.45
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

GlucoTrack Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GlucoTrack Announcement Details

Quarter
Q4 2022
Date
3/31/2023
Time
N/A

Conference Call Resources

GlucoTrack Earnings Headlines

Glucotrack, Inc. Achieves ISO 13485:2016 Certification for Quality Management On January 21, 2025, Glucotrack, Inc. (NASDAQ: GCTK) made a significant stride by acquiring ISO13485:2016 certification from the British Standards Institute. The certific
January 22 at 2:11 AM | americanbankingnews.com
Glucotrack Announces ISO 13485:2016 Certification
January 21 at 8:01 AM | globenewswire.com
Did You See Trump’s Manhattan Project Bombshell?
This secret document contains stunning details about Donald Trump’s very first order of business… the minute he steps back into the White House. Because if what’s in this leaked document is even half true (and trust me, it comes from a very, very credible source)... Trump’s first Executive Order would easily be the boldest, most mind-blowing and daring American initiative ANY U.S. President has launched in over 80 years.
January 22, 2025 | Banyan Hill Publishing (Ad)
GlucoTrack (NASDAQ: IGAP)
January 16, 2025 | fool.com
GlucoTrack appoints Ted Williams as VP, regulatory affairs
January 16, 2025 | markets.businessinsider.com
Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs
January 15, 2025 | globenewswire.com
See More GlucoTrack Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GlucoTrack? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GlucoTrack and other key companies, straight to your email.

About GlucoTrack

GlucoTrack (NASDAQ:GCTK), a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.

View GlucoTrack Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles